Take the Diabetes Health Pump Survey
See What's Inside
Read this FREE issue now
For healthcare professionals only
  • 12 Tips for Traveling With Diabetes
See the entire table of contents here!

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter
Latest
Popular
Top Rated
Type 2 Issues Archives
Print | Email | Share | Comments (0)

FDA Accepts Application to Review Dapagliflozin, a Type 2 Treatment


Mar 22, 2011

AstraZeneca, Bristol-Myers Squibb

The U.S. Food and Drug Administration has accepted an application to review dapagliflozin, a drug for the treatment of type 2 diabetes that is being developed by Bristol-Myers Squibb and AstraZeneca.

Dapagliflozin differs from conventional type 2 drug treatments that target insulin production or use. Instead, dapagliflozin targets sodium-glucose cotransporter-2 (SGLT2), which is located in the kidney. By doing so, the drug encourages the excretion of excess glucose and calories. (Its mechanism of action is described in the recent Diabetes Health article, "Flushing Away High Blood Sugar.")

FDA approval could come by late October this year. The manufacturers have also applied for European approval with the European Medicines Agency.

Before applying to U.S. and European regulators, Bristol-Meyers and AstraZeneca studied dapagliflozin's effects on 6,000 subjects enrolled in 40 clinical studies. For the U.S. market, they also tracked any correlation between the use of the drug and potential cardiovascular problems.


Categories: Blood Sugar, Diabetes, Diabetes, Food, Health Care, Heart Care & Heart Disease, High Blood Sugar, Insulin, Insulin Resistance, Research, Type 2 Issues



You May Also Be Interested In...


Comments


Add your comments about this article below. You can add comments as a registered user or anonymously. If you choose to post anonymously your comments will be sent to our moderator for approval before they appear on this page. If you choose to post as a registered user your comments will appear instantly.

When voicing your views via the comment feature, please respect the Diabetes Health community by refraining from comments that could be considered offensive to other people. Diabetes Health reserves the right to remove comments when necessary to maintain the cordial voice of the diabetes community.

For your privacy and protection, we ask that you do not include personal details such as address or telephone number in any comments posted.

Don't have your Diabetes Health Username? Register now and add your comments to all our content.

Have Your Say...


Username: Password:
Comment:
©1991-2014 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.